Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (11086)	3/31/2004 1:28:30 PM
From: Biomaven	Respond to of 52153

confirming laboratory studies that showed a greater anti-tumor effect for ovarian cancer at lower dosages for phenoxodiol I went back and looked at the 2003 Oncogene paper on ovarian cells and phenoxodiol. They showed a graph of cell viability vs. dose for 8 ovarian ca cell lines and normal ovarian epithelial cells. For normal cells, very low-dose phenox (0.01 micro g/ml) actually showed reduced viability, but this normalized at higher doses starting at .1 through 10 micro g/ml). Six of the ca cell lines showed a dose-response, with the only substantial effect (less than 50% viability) happening at the biggest dose of 10. In the two most sensitive lines, the maximum effect (only about 10% viability) happened earlier, at 1.0 micro g/ml, with the effect at 10.0 somewhat less (about 25% viability). So I guess there is some moderate evidence in these two cell lines for a biphasic response. But it's not very dramatic overall. Of course it's very hard to go from in vitro measurements to real life effects, but it's nice to try to check for an unknown company whether they are prevaricating in their PR's or not. They may of course have more in vitro. data not presented in the paper, but based solely on what's presented they get a "maybe right" grade. <g> Peter